Gen-Probe Submits PMA to FDA for Prostate Cancer Assay | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Gen-Probe announced after the close of market on Tuesday that it has filed a Premarket Approval application with the US Food and Drug Administration for its prostate cancer assay.

The test, called Progensa PCA3, may help in determining whether repeat biopsies are needed in men suspected of having prostate cancer, Gen-Probe said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.